Samsung Biologics Co.,Ltd. (KRX:207940)

Samsung Biologics Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	5,504,838	4,547,322	3,694,589	3,001,295	1,568,007	1,164,777
Other Revenue	-	-	-	-0	-	-
Revenue	5,504,838	4,547,322	3,694,589	3,001,295	1,568,007	1,164,777
Revenue Growth (YoY)	26.13%	23.08%	23.10%	91.41%	34.62%	66.02%
Cost of Revenue	2,427,021	2,273,151	1,900,080	1,540,526	844,657	751,189
Gross Profit	3,077,818	2,274,171	1,794,509	1,460,769	723,350	413,588
Selling, General & Admin	831,092	758,510	535,421	380,456	169,630	110,009
Research & Development	173,756	144,649	81,588	45,884	954.22	-
Amortization of Goodwill & Intangibles	16,390	13,629	9,977	7,700	4,572	3,950
Other Operating Expenses	12,746	11,145	10,339	7,448	1,804	1,789
Operating Expenses	1,061,017	954,119	680,829	477,142	186,040	120,802
Operating Income	2,016,800	1,320,052	1,113,680	983,627	537,309	292,787
Interest Expense	-52,955	-50,057	-81,596	-64,064	-14,707	-16,086
Interest & Investment Income	52,659	63,839	95,650	53,293	9,656	13,140
Earnings From Equity Investments	18,094	2,660	-499.42	27,260	13,853	-17,768
Currency Exchange Gain (Loss)	50,425	77,140	-11,186	-63,503	17,874	-3,196
Other Non Operating Income (Expenses)	27,540	19,789	2,652	2,347	4,494	3.96
EBT Excluding Unusual Items	2,112,562	1,433,423	1,118,701	938,960	568,479	268,882
Gain (Loss) on Sale of Investments	1,136	597.28	5,152	72,653	269.12	303.96
Gain (Loss) on Sale of Assets	-2,618	-2,199	-3,866	-2,588	-7,466	-1,841
Asset Writedown	-61,770	-61,770	-	-	-	-1,352
Pretax Income	2,049,311	1,370,052	1,119,987	1,009,025	561,283	265,992
Income Tax Expense	453,418	286,736	262,296	210,968	167,693	25,017
Earnings From Continuing Operations	1,595,893	1,083,316	857,691	798,056	393,589	240,975
Net Income	1,595,893	1,083,316	857,691	798,056	393,589	240,975
Net Income to Common	1,595,893	1,083,316	857,691	798,056	393,589	240,975
Net Income Growth	51.63%	26.31%	7.47%	102.76%	63.33%	18.76%
Shares Outstanding (Basic)	46	46	46	45	43	43
Shares Outstanding (Diluted)	46	46	46	45	43	43
Shares Change (YoY)	-	-	1.95%	5.51%	-	-
EPS (Basic)	34475.27	23402.33	18528.27	17592.79	9146.19	5599.75
EPS (Diluted)	34474.63	23402.33	18528.27	17577.11	9146.19	5599.75
EPS Growth	51.63%	26.31%	5.41%	92.18%	63.33%	18.76%
Free Cash Flow	791,557	355,682	671,158	-3,792	48,343	62,425
Free Cash Flow Per Share	17099.61	7683.62	14498.68	-83.52	1123.38	1450.63
Gross Margin	55.91%	50.01%	48.57%	48.67%	46.13%	35.51%
Operating Margin	36.64%	29.03%	30.14%	32.77%	34.27%	25.14%
Profit Margin	28.99%	23.82%	23.21%	26.59%	25.10%	20.69%
Free Cash Flow Margin	14.38%	7.82%	18.17%	-0.13%	3.08%	5.36%
EBITDA	2,688,135	1,919,154	1,603,462	1,291,892	699,098	436,475
EBITDA Margin	48.83%	42.20%	43.40%	43.04%	44.59%	37.47%
D&A For EBITDA	671,335	599,101	489,782	308,264	161,789	143,688
EBIT	2,016,800	1,320,052	1,113,680	983,627	537,309	292,787
EBIT Margin	36.64%	29.03%	30.14%	32.77%	34.27%	25.14%
Effective Tax Rate	22.13%	20.93%	23.42%	20.91%	29.88%	9.40%
Advertising Expenses	-	17,042	11,916	8,829	5,349	4,396

Source: S&P Global Market Intelligence. Standard template. Financial Sources.